Precision screening identifies mitoxantrone as a multitarget inhibitor in ageing-associated cancers with extensive computational validation and doxorubicin comparison
Favorite
Share
More Options
33

Open in WPS to view all 33 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
